Suven Life Sciences Limited has informed the Exchange regarding Investor Presentation
SUVEN Life Sciences
Communication to investors June 2019
14-Aug-19
2019-20 Q1 results
Risk statement
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
14-Aug-19
2019-20 Q1 results
FINANCIAL QUICK VIEW Quarter 1 – June 2019
Growth in Revenue
Growth in PAT
Growth in EBIDTA
Growth Pre-R&D EBIDTA
Q1-FY20 to Q4-FY19
-21.42%
-16.62%
-14.68%
-16.37%
Q1-FY20 to Q1-FY19
1.10%
47.38%
40.21%
28.89%
Increase in R&D costs
-26.68%
-18.06%
14-Aug-19
2019-20 Q1 results
MAJOR PROFITABILITY RATIOS
30 Jun 2019
31 Mar 2019
30 Jun 2018
PAT to Income
28.29%
26.47%
19.41%
EBIDTA to Income
Cash Flow to Income
Pre-R&D EBITDA to Income
46.06%
42.42%
33.21%
31.04%
28.60%
22.16%
52.55%
49.37%
41.22%
R&D to Income
6.49%
6.95%
8.00%
14-Aug-19
2019-20 Q1 results
INCOME COMPARISON
INR Million
2,570.53
1,997.90
2,019.93
3,000.00
2,500.00
2,000.00
1,500.00
1,000.00
500.00
-
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
PROFIT COMPARISON
INR Million
680.47
571.43
800.00
700.00
600.00
500.00
400.00
300.00
200.00
100.00
-
387.73
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
EBIDTA COMPARISON
INR Million
1,090.48
930.39
663.59
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
R & D – EXPENDITURE
INR Million
178.69
159.89
131.01
200.00
180.00
160.00
140.00
120.00
100.00
80.00
60.00
40.00
20.00
-
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
PRE-R&D EBIDTA
INR Million
1,269.17
1,061.41
823.47
1,400.00
1,200.00
1,000.00
800.00
600.00
400.00
200.00
-
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
PRE-R&D CASHFLOW
INR Million
913.79
757.95
602.70
1,000.00
900.00
800.00
700.00
600.00
500.00
400.00
300.00
200.00
100.00
-
Q1 Jun 18
Q4 Mar 19
Q1 Jun 19
14-Aug-19
2019-20 Q1 results
Financial Snapshot
All figures are in INR Million, other than ratios and EPS
14-Aug-19
2019-20 Q1 results
News Updates
• SUVN-502 Phase 2A clinical trial, indicated for patients with
moderate Alzheimer’s undertaken in USA completed with the Last Patient Last Visit (LPLV) on May 23, 2019.
• The completed clinical trial had an enrollment of 564 patients
against the target of 537 patients in the study.
• The outcome of SUVN-502 is expected by Sept/Oct 2019
after completion of statistical analysis of the data.
• Suven Life Sciences presented in AAIC 2019, held in Los
Angeles in July 2019.
14-Aug-19
2019-20 Q1 results
News Updates
• During the period Suven secures 10 product patents covering
regions/countries – Europe, India, Israel, Japan, Macau, Mexico, New Zealand, Sri Lanka and USA.
• SUVN-G3031 Phase 2 clinical trial, indicated for Narcolepsy
(with and without Cataplexy), initiated in USA with an estimated enrollment of minimum of 114 patients and maximum of 171 patients in the study.
• Suven Life Sciences submitted application to National
Company Law Tribunal (NCLT) for Demerger of Suven into two companies, focused on Discovery Research and CRAMS operations. For more info on the scheme of demerger please follow the link: http://suven.com/schemeofarrangement.aspx
14 Aug 2019
2019-20 Q1 results